Why is PSA no longer recommended?

Why is PSA no longer recommended?

The PSA (Prostate-Specific Antigen) test, once widely used to detect prostate cancer, has faced significant controversy in recent years. In 2012, the United States Preventive Services Task Force (USPSTF) recommended against the use of PSA screening in healthy men, citing potential harms associated with the test. In 2019, the American Urological Association (AUA) followed suit, revising their guidelines to reflect the same stance. But why has PSA screening lost its appeal? Let’s dive into the reasons.

Limited accuracy

The PSA test is not perfect. Elevated PSA levels do not always indicate the presence of cancer, and low levels do not guarantee its absence. False positive results, where a person tests positive for cancer despite not having it, are common, leading to unnecessary biopsies and further testing. Conversely, false negative results, where a person tests negative for cancer despite having it, can delay diagnosis and treatment.

Overdiagnosis and overtreatment

The PSA test has been accused of overdiagnosing and overtreating low-risk prostate cancers. This can lead to unnecessary procedures, including surgery, radiation therapy, and hormone therapy, which can have serious side effects. Men may undergo treatment for slow-growing cancers that would never have caused symptoms or affected their mortality.

Harms associated with biopsy

Prostate biopsies, often performed based on elevated PSA levels, carry their own set of risks and complications. These include:

• Bleeding: A common complication, bleeding can range from mild to severe.
• Infection: Bacterial infections can occur, requiring antibiotics.
• Urinary retention: The test can cause temporary or permanent urinary retention.
• Pain: Men may experience pain during the procedure.

Alternative options

With the limitations of PSA testing and the risks associated with biopsies, healthcare providers are looking for alternative methods to diagnose and monitor prostate cancer. Some options include:

• Prostate MRI: Magnetic Resonance Imaging (MRI) can provide more accurate images of the prostate, potentially reducing the need for biopsies.
• Prostate biopsy with MRI fusion: Combining MRI images with prostate biopsies can increase accuracy and reduce the risk of unnecessary biopsies.
• Active surveillance: Closely monitoring men with low-risk prostate cancer can help identify when treatment is necessary.

New guidelines and recommendations

In response to the limitations of PSA testing, several organizations have revised their guidelines and recommendations. These include:

Conclusion

The PSA test, once a cornerstone of prostate cancer screening, has faced significant controversy in recent years. The limited accuracy, overdiagnosis, and overtreatment associated with the test have led many healthcare providers to question its use. Alternative options, such as prostate MRI and active surveillance, are being explored to improve diagnosis and monitoring. Until more accurate and effective screening methods are developed, it is essential for men to have open and informed discussions with their healthcare providers about their individual risks and needs.